Literature DB >> 9554316

Basic psychopharmacology of antidepressants, part 1: Antidepressants have seven distinct mechanisms of action.

S M Stahl1.   

Abstract

Distinct pharmacologic mechanisms allow the antidepressants to be separated into seven different classes. These basic pharmacologic concepts can explain not only the therapeutic actions, but also the side effects of the wide range of antidepressants currently available. The two classical mechanisms are those of tricyclic antidepressants (TCAs) and monoamine oxidase inhibitors (MAOIs). The most widely prescribed agents are the serotonin selective reuptake inhibitors (SSRIs). Three other classes of antidepressants, like the SSRIs, increase serotonergic neurotransmission, but they also have additional actions, namely dual serotonin and norepinephrine reuptake inhibition (venlafaxine); serotonin-2 antagonism/reuptake inhibition (nefazodone); and alpha2 antagonism plus serotonin-2 and -3 antagonism (mirtazapine). The selective norepinephrine and dopamine reuptake inhibitor bupropion defines a novel class of antidepressant that has no direct actions on the serotonin system.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9554316

Source DB:  PubMed          Journal:  J Clin Psychiatry        ISSN: 0160-6689            Impact factor:   4.384


  56 in total

1.  Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline.

Authors:  A G Teschemacher; E P Seward; J C Hancox; H J Witchel
Journal:  Br J Pharmacol       Date:  1999-09       Impact factor: 8.739

Review 2.  Antidepressants as analgesics: an overview of central and peripheral mechanisms of action.

Authors:  J Sawynok; M J Esser; A R Reid
Journal:  J Psychiatry Neurosci       Date:  2001-01       Impact factor: 6.186

Review 3.  Stuttering: an update for physicians.

Authors:  D Costa; R Kroll
Journal:  CMAJ       Date:  2000-06-27       Impact factor: 8.262

4.  How does this happen? Part I: mechanisms of adverse drug reactions associated with psychotropic medications.

Authors:  Dean Elbe; Robert Savage
Journal:  J Can Acad Child Adolesc Psychiatry       Date:  2010-02

Review 5.  Disturbed development of the enteric nervous system after in utero exposure of selective serotonin re-uptake inhibitors and tricyclic antidepressants. Part 1: Literature review.

Authors:  Cynthia M Nijenhuis; Peter G J ter Horst; Lolkje T W de Jong-van den Berg; Bob Wilffert
Journal:  Br J Clin Pharmacol       Date:  2012-01       Impact factor: 4.335

6.  A double-blind, placebo-controlled study of selegiline transdermal system in depressed adolescents.

Authors:  Melissa P DelBello; Thomas J Hochadel; Kimberly Blanchard Portland; Albert J Azzaro; Alain Katic; Arif Khan; Graham Emslie
Journal:  J Child Adolesc Psychopharmacol       Date:  2014-06-23       Impact factor: 2.576

7.  Norepinephrine transporter inhibitors and their therapeutic potential.

Authors:  Jia Zhou
Journal:  Drugs Future       Date:  2004-12       Impact factor: 0.148

Review 8.  HCN Channel Targets for Novel Antidepressant Treatment.

Authors:  Stacy M Ku; Ming-Hu Han
Journal:  Neurotherapeutics       Date:  2017-07       Impact factor: 7.620

9.  The psychoactive drug Escitalopram affects swimming behaviour and increases boldness in zebrafish (Danio rerio).

Authors:  Sebastian V Nielsen; Martin Kellner; Per G Henriksen; Håkan Olsén; Steen H Hansen; Erik Baatrup
Journal:  Ecotoxicology       Date:  2018-03-14       Impact factor: 2.823

10.  Patterns and predictors of antidepressant use in ambulatory cancer patients with common solid tumors.

Authors:  Michael J Fisch; Fengmin Zhao; Judith Manola; Andrew H Miller; William F Pirl; Lynne I Wagner
Journal:  Psychooncology       Date:  2014-06-14       Impact factor: 3.894

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.